Skip to content

Brief diagnostic method for COPD: the diagnostic significance of Chinese version of HARQ

Brief diagnostic method for COPD: the diagnostic significance of Chinese version of HARQ

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044899
Enrollment
Unknown
Registered
2021-03-31
Start date
2021-03-28
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Gold Standard:Pulmonary function test: FEV1/FVC=12%, absolute value>=200mL.
Index test:Hull&#32

Sponsors

Shanghai Tongji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Aged 40 to 85 years; 2.According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)20, the ratio of FEV1 to forced vital capacity (FEV1/FVC) after bronchodilators will be used <70% are diagnosed as COPD; 3.No pulmonary heart disease, or pulmonary heart disease but the primary disease is COPD; 4.If COPD is stable with other diseases, other diseases are in a relatively stable period; 5.Volunteer to participate and sign informed The patient with the consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with primary diseases with more serious other organs; 2.Patients with mental illness or other reasons who cannot cooperate with the collection of syndrome information.

Design outcomes

Primary

MeasureTime frame
Hull airway reflux questionnaire;

Countries

China

Contacts

Public ContactWen Siwan

Shanghai Tongji Hospital

wensiwan@qq.com+86 13585560890

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026